Pascal Finetti
Overview
Explore the profile of Pascal Finetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
191
Citations
6426
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Wang X, Semba T, Manyam G, Wang J, Shao S, Bertucci F, et al.
Sci Adv
. 2022 Dec;
8(50):eabn7983.
PMID: 36525493
Inflammatory breast cancer (IBC), the most aggressive breast cancer subtype, is driven by an immunosuppressive tumor microenvironment (TME). Current treatments for IBC have limited efficacy. In a clinical trial (NCT01036087),...
22.
Sanson R, Lazzara S, Cune D, Pitasi C, Trentesaux C, Fraudeau M, et al.
Cell Mol Gastroenterol Hepatol
. 2022 Nov;
15(3):689-715.
PMID: 36356835
Background & Aims: Axin1 is a negative regulator of wingless-type MMTV integration site family, member 1 (Wnt)/β-catenin signaling with tumor-suppressor function. The Wnt pathway has a critical role in the...
23.
de Rauglaudre B, Finetti P, Birnbaum D, Lopez M, Bertucci F, Mamessier E
Mol Cancer Ther
. 2022 Nov;
21(11):1742-1743.
PMID: 36325689
No abstract available.
24.
Boudin L, de Nonneville A, Finetti P, Mescam L, Le Cesne A, Italiano A, et al.
J Transl Med
. 2022 Oct;
20(1):464.
PMID: 36221119
Background: Soft tissue sarcomas (STS) are heterogeneous and pro-metastatic tumors. Identification of accurate prognostic factors and novel therapeutic targets are crucial. CSPG4 is a cell surface proteoglycan with oncogenic functions....
25.
Manai M, ELBini-Dhouib I, Finetti P, Bichiou H, Reduzzi C, Aissaoui D, et al.
Cells
. 2022 Sep;
11(18).
PMID: 36139501
Inflammatory breast cancer (IBC) is the most pro-metastatic form of breast cancer (BC). We previously demonstrated that protein overexpression of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) protein was associated with...
26.
Daulat A, Wagner M, Audebert S, Kowalczewska M, Ariey-Bonnet J, Finetti P, et al.
J Cell Sci
. 2022 Aug;
135(17).
PMID: 35971817
Upregulation of the developmental Wnt planar cell polarity (Wnt/PCP) pathway is observed in many cancers and is associated with cancer development. We have recently shown that PRICKLE1, a core Wnt/PCP...
27.
Le T, Cherif C, Omabe K, Paris C, Lannes F, Audebert S, et al.
Mol Ther
. 2022 Aug;
31(2):471-486.
PMID: 35965411
The heat shock protein 27 (Hsp27) has emerged as a principal factor of the castration-resistant prostate cancer (CRPC) progression. Also, an antisense oligonucleotide (ASO) against Hsp27 (OGX-427 or apatorsen) has...
28.
de Nonneville A, Salas S, Bertucci F, Sobinoff A, Adelaide J, Guille A, et al.
EMBO Mol Med
. 2022 Aug;
14(10):e15859.
PMID: 35920001
In some types of cancer, telomere length is maintained by the alternative lengthening of telomeres (ALT) mechanism. In many ALT cancers, the α-thalassemia/mental retardation syndrome X-linked (ATRX) gene is mutated...
29.
Nigri J, Leca J, Tubiana S, Finetti P, Guillaumond F, Martinez S, et al.
Sci Signal
. 2022 Aug;
15(745):eabg8191.
PMID: 35917363
In pancreatic ductal adenocarcinoma (PDAC), signaling from stromal cells is implicated in metastatic progression. Tumor-stroma cross-talk is often mediated through extracellular vesicles (EVs). We previously reported that EVs derived from...
30.
Boudin L, de Nonneville A, Finetti P, Guittard G, Nunes J, Birnbaum D, et al.
Cancers (Basel)
. 2022 Jul;
14(14).
PMID: 35884417
Strategies are being explored to increase the efficiency of immune checkpoint inhibitors (ICIs) targeting PD1/PDL1 in triple-negative breast cancer (TNBC), including combination with therapies inhibiting intracellular immune checkpoints such as...